MedTrace Logo

Study With Rupatadine in Mosquito-Bite Allergic Adult Subjects

NCT00258141 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2005-11-24

No results posted yet for this study

Summary

The study will find out how effective rupatadine is in the treatment of mosquito bite symptoms in adult patients allergic to mosquito bites.

Conditions

  • Allergy

Interventions

DRUG

Rupatadine

DRUG

Placebo

Sponsors & Collaborators

  • J. Uriach and Company

    lead INDUSTRY

Principal Investigators

  • Timo Reunala, Prof. · Medical School, University of Tampere and Tampere University Hospital

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Countries

  • Finland

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00258141 on ClinicalTrials.gov